Furthermore, mutated TP53 inhibited the virus response and interferon release in DLBCL, and subsequently induced the suppressive TME with the lower infiltration of T-cells, contributing to the worse outcome of TP53-mutant patients under immune-targeted therapy (41). The gene discussed is TP53; the disease is diffuse large B-cell lymphoma.